Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Arbutus Biopharma Corp | exhibit321q32018.htm |
| EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corp | exhibit312q32018.htm |
| EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corp | exhibit311q32018.htm |
| EX-10.1 - EXHIBIT 10.1 - Arbutus Biopharma Corp | exhibit101execemploymentgp.htm |
| EX-3.1 - EXHIBIT 3.1 - Arbutus Biopharma Corp | exhibit31amendmenttoarticl.htm |
| 10-Q - 10-Q - Arbutus Biopharma Corp | arbutusq32018.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the “Company”) for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I David Hastings, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company. |
Date: November 7, 2018
/s/ David Hastings | |
Name: David Hastings | |
Title: Chief Financial Officer | |